1
|
Corato V, Vorpahl C, Sedlak K, Anvar V, Bennet J, Biancolini M, Bonne F, Bonifetto R, Boso D, Brighenti A, Bruzzone P, Celentano G, della Corte A, De Marzi G, D'Auria V, Demattè F, Dembkowska A, Dicuonzo O, Zignani CF, Fietz W, Frittitta C, Giannini L, Giorgetti F, Guarino R, Heller R, Hoa C, Huguet M, Jiolat G, Kumar M, Lacroix B, Lewandowska M, Misiara N, Morici L, Muzzi L, Nickel D, Nicollet S, Nijhuis A, Nunio F, Portafaix C, Sarasola X, Savoldi L, Tiseanu I, Tomassetti G, Torre A, Turtù S, Uglietti D, Vallcorba R, Weiss KP, Wesche R, Wolf M, Yagotintsev K, Zani L, Zanino R, Zappatore A. The DEMO magnet system – Status and future challenges. Fusion Engineering and Design 2022. [DOI: 10.1016/j.fusengdes.2021.112971] [Citation(s) in RCA: 13] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
2
|
Papa F, Utili M, Venturini A, Caruso G, Savoldi L, Bonifetto R, Valerio D, Allio A, Collaku A, Tarantino M. Engineering design of a Permeator Against Vacuum mock-up with niobium membrane. Fusion Engineering and Design 2021. [DOI: 10.1016/j.fusengdes.2021.112313] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
3
|
Froio A, Bertinetti A, Ghidersa BE, Hernández FA, Savoldi L, Zanino R. Analysis of the Flow Distribution in the Back Supporting Structure Manifolds of the HCPB Breeding Blanket for the EU DEMO Fusion Reactor. Fusion Science and Technology 2019. [DOI: 10.1080/15361055.2019.1600348] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Affiliation(s)
- A. Froio
- Politecnico di Torino, Dipartimento Energia, NEMO Group, Torino, Italy
| | - A. Bertinetti
- Politecnico di Torino, Dipartimento Energia, NEMO Group, Torino, Italy
| | - B.-E. Ghidersa
- Karlsruher Institut für Technologie, Institut für Neutronenphysik und Reaktortechnik, Karlsruhe, Germany
| | - F. A. Hernández
- Karlsruher Institut für Technologie, Institut für Neutronenphysik und Reaktortechnik, Karlsruhe, Germany
| | - L. Savoldi
- Politecnico di Torino, Dipartimento Energia, NEMO Group, Torino, Italy
| | - R. Zanino
- Politecnico di Torino, Dipartimento Energia, NEMO Group, Torino, Italy
| |
Collapse
|
4
|
Bonifetto R, Pedroni N, Savoldi L, Zanino R. Identification of the Postulated Initiating Events of Accidents Occurring in a Toroidal Field Magnet of the EU DEMO. Fusion Science and Technology 2019. [DOI: 10.1080/15361055.2019.1602398] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Affiliation(s)
- R. Bonifetto
- Politecnico di Torino, NEMO Group, Dipartimento Energia, Torino, Italy
| | - N. Pedroni
- Politecnico di Torino, NEMO Group, Dipartimento Energia, Torino, Italy
| | - L. Savoldi
- Politecnico di Torino, NEMO Group, Dipartimento Energia, Torino, Italy
| | - R. Zanino
- Politecnico di Torino, NEMO Group, Dipartimento Energia, Torino, Italy
| |
Collapse
|
5
|
Froio A, Del Nevo A, Martelli E, Savoldi L, Zanino R. Parametric thermal-hydraulic analysis of the EU DEMO Water-Cooled Lithium-Lead First Wall using the GETTHEM code. Fusion Engineering and Design 2018. [DOI: 10.1016/j.fusengdes.2018.10.003] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
6
|
Cismondi F, Boccaccini L, Aiello G, Aubert J, Bachmann C, Barrett T, Barucca L, Bubelis E, Ciattaglia S, Del Nevo A, Diegele E, Gasparotto M, Di Gironimo G, Di Maio P, Hernandez F, Federici G, Fernández-Berceruelo I, Franke T, Froio A, Gliss C, Keep J, Loving A, Martelli E, Maviglia F, Moscato I, Mozzillo R, Poitevin Y, Rapisarda D, Savoldi L, Tarallo A, Utili M, Vala L, Veres G, Zanino R. Progress in EU Breeding Blanket design and integration. Fusion Engineering and Design 2018. [DOI: 10.1016/j.fusengdes.2018.04.009] [Citation(s) in RCA: 37] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
7
|
Corato V, Bagni T, Biancolini M, Bonifetto R, Bruzzone P, Bykovsky N, Ciazynski D, Coleman M, della Corte A, Dembkowska A, Di Zenobio A, Eisterer M, Fietz W, Fischer D, Gaio E, Giannini L, Giorgetti F, Heller R, Ivashov I, Lacroix B, Lewandowska M, Maistrello A, Morici L, Muzzi L, Nijhuis A, Nunio F, Panin A, Sarasola X, Savoldi L, Sedlak K, Stepanov B, Tomassetti G, Torre A, Turtù S, Uglietti D, Vallcorba R, Weiss KP, Wesche R, Wolf M, Yagotintsev K, Zani L, Zanino R. Progress in the design of the superconducting magnets for the EU DEMO. Fusion Engineering and Design 2018. [DOI: 10.1016/j.fusengdes.2018.05.065] [Citation(s) in RCA: 36] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
8
|
Boni C, Moretti G, Savoldi L, Armaroli L, Barbieri W, Bisagni G, Caroggio A, Iotti C, Pedroni C, Manenti AL, Rondini E, Sassi M, Zadro A. Neoadjuvant Chemotherapy with Continuous Infusion of Cisplatin and Fluorouracil in Stage II-IV, M0 Squamous Cell Carcinoma of the Head and Neck. Tumori 2018; 82:567-72. [PMID: 9061065 DOI: 10.1177/030089169608200610] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Aims and Background The aim of the study was to assess the activity and the toxicity of cisplatin (DDP) and fluorouracil (FU) administered by continuous infusion as neoadjuvant chemotherapy for patients with stage II-IV, MO squamous cell carcinoma of the head and neck. Methods Thirty previously untreated patients were submitted to chemotherapy with DDP (20 mg/m2) and FU (1000 mg/m2), both in continuous infusion for 5 days, repeated every 21 days, for a maximum of 5 cycles. Following completion of chemotherapy, the patients underwent radiotherapy; in some patients surgery was performed immediately after chemotherapy. All patients were monitored for response, time to failure, survival, treatment-related events and toxicity. Results All patients were evaluated for response; after chemotherapy the complete response rate was 27% and the partial response rate 33%. Twenty-four patients underwent radiotherapy: the overall response rate was 83% (complete response 79%). After a median follow-up of 34 months, the median survival time was 22 months with a median time to failure of 15 months. Acute vascular accidents were the main and unexpected adverse events, with 2 deaths for pulmonary embolism and 1 for stroke. The response rate to the regimen does not seem to be better than that obtained with the standard combination of cisplatin bolus and fluorouracil continuous infusion. The disadvantage of the regimen is that it causes more discomfort for the patient in that it requires hospitalization. Conclusions For this reason, we believe that there are no elements for recommending the schedule as neoadjuvant treatment of patients with squamous cell carcinoma of the head and neck or as an experimental arm in a randomized trial.
Collapse
Affiliation(s)
- C Boni
- Servizio di Oncologia Medica, Azienda Ospedaliera di Reggio Emilia, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Bisagni G, Boni C, Manenti AL, Moretti G, Rondini E, Sassi M, Zadro A, Savoldi L. Ifosfamide Bolus Followed by Five Days Continuous Infusion in Extensively Pretreated Patients with Advanced Breast Cancer: A Phase II Study. Tumori 2018; 84:659-61. [PMID: 10080671 DOI: 10.1177/030089169808400608] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
PURPOSE A phase II study with ifosfamide in pretreated patients with advanced breast cancer was performed to determine the objective response rate, the toxicity and the feasibility of the regimen. METHODS & STUDY DESIGN Patients enrolled had advanced breast cancer pretreated with at least one previous regimen of chemotherapy for advanced disease. Treatment consisted of ifosfamide infused at a dose of 2 g/m2 iv in 4 hrs followed by ifosfamide, 8 g/m2 iv in 120 hrs in ambulatory treatment, using a portable external pump system. The total dose of ifosfamide was 10 g/m2; mesna (4 g/m2 iv) was administered mixed with ifosfamide in 120 hrs Cycles were repeated every 3 weeks. Three patients were pretreated with neoadjuvant and 15 with adjuvant chemotherapy. All patients were treated for advanced disease (median number of regimens, 1; range, 1-3): 21 with the cyclophosphamide-containing regimen and 15 with adryamicin. Sixteen patients received one or more lines of endocrine therapy. Fifteen patients had dominant site in viscera, 6 in bone, and only one in soft tissue; 17 patients had more than one site of disease. RESULTS Twenty-two patients were enrolled and all were assessable for response and toxicity. A partial response was reached in 5 patients (23%; 95% confidence limits 5% to 60%). Hematologic toxicity was the dose-limiting side effect; grade 4 leukopenia occurred in 10 patients (46%). CONCLUSIONS Considering the response rate obtained in our series of intensively pretreated patients, the results seem to indicate that the regimen is active and could be included among the possible options in the treatment of patients with refractory, poor-prognosis, advanced breast carcinoma.
Collapse
Affiliation(s)
- G Bisagni
- Medical Oncology Service, General Hospital, Reggio Emilia, Italy
| | | | | | | | | | | | | | | |
Collapse
|
10
|
Nallo G, Carli S, Caruso G, Crisanti F, Mazzitelli G, Savoldi L, Subba F, Zanino R. Modeling the lithium loop in a liquid metal pool-type divertor. Fusion Engineering and Design 2017. [DOI: 10.1016/j.fusengdes.2017.07.004] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
11
|
Di Zenobio A, Albanese R, Anemona A, Biancolini M, Bonifetto R, Brutti C, Corato V, Crisanti F, della Corte A, De Marzi G, Fiamozzi Zignani C, Giorgetti F, Messina G, Muzzi L, Savoldi L, Tomassetti G, Turtù S, Villone F, Zappatore A. DTT device: Conceptual design of the superconducting magnet system. Fusion Engineering and Design 2017. [DOI: 10.1016/j.fusengdes.2017.03.102] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
12
|
Froio A, Casella F, Cismondi F, Del Nevo A, Savoldi L, Zanino R. Dynamic thermal-hydraulic modelling of the EU DEMO WCLL breeding blanket cooling loops. Fusion Engineering and Design 2017. [DOI: 10.1016/j.fusengdes.2017.01.062] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
13
|
Bertinetti A, Avramidis K, Albajar F, Cau F, Cismondi F, Rozier Y, Savoldi L, Zanino R. Multi-physics analysis of a 1 MW gyrotron cavity cooled by mini-channels. Fusion Engineering and Design 2017. [DOI: 10.1016/j.fusengdes.2017.05.016] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
14
|
Jelonnek J, Aiello G, Alberti S, Avramidis K, Bertinetti A, Bruschi A, Chelis J, Franke T, Gantenbein G, Garavaglia S, Granucci G, Grossetti G, Illy S, Ioannidis Z, Jin J, Kalaria P, Latsas G, Laqua H, Leggieri A, Legrand F, Marek A, Pagonakis I, Peponis D, Savoldi L, Rzesnicki T, Ruess S, Ruess T, Scherer T, Schmid M, Strauss D, Tigelis I, Thumm M, Tran M, Wilde F, Wu C, Zanino R, Zein A. European research activities towards a future DEMO gyrotron. EPJ Web Conf 2017. [DOI: 10.1051/epjconf/201714904007] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
15
|
Ragazzi M, Bisagni A, Gasparini E, Kuhn E, Bassano C, Tamagnini I, Foroni M, Bortesi M, Falco G, Ferrari G, Braglia L, Savoldi L, Bologna A, Di Cicilia R, Bisagni G, Gardini G. Impact of 2013 ASCO/CAP guidelines on HER2 determination of invasive breast cancer: A single institution experience using frontline dual-color FISH. Breast 2017; 34:65-72. [DOI: 10.1016/j.breast.2017.05.001] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2017] [Revised: 04/20/2017] [Accepted: 05/04/2017] [Indexed: 11/24/2022] Open
|
16
|
Savoldi L, Bonifetto R, Brighenti A, Corato V, Muzzi L, Turtu’ S, Zanino R, Zappatore A. Quench Propagation in a TF Coil of the EU DEMO. Fusion Science and Technology 2017. [DOI: 10.1080/15361055.2017.1333866] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Affiliation(s)
- L. Savoldi
- Politecnico di Torino, NEMO Group, Dipartimento Energia, Torino, Italy
| | - R. Bonifetto
- Politecnico di Torino, NEMO Group, Dipartimento Energia, Torino, Italy
| | - A. Brighenti
- Politecnico di Torino, NEMO Group, Dipartimento Energia, Torino, Italy
| | | | | | | | - R. Zanino
- Politecnico di Torino, NEMO Group, Dipartimento Energia, Torino, Italy
| | - A. Zappatore
- Politecnico di Torino, NEMO Group, Dipartimento Energia, Torino, Italy
| |
Collapse
|
17
|
D’Auria V, Dulla S, Ravetto P, Savoldi L, Utili M, Zanino R. Tritium Extraction from Lithium-Lead in the EU DEMO Blanket Using Permeator Against Vacuum. Fusion Science and Technology 2017. [DOI: 10.1080/15361055.2017.1291252] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Affiliation(s)
- V. D’Auria
- NEMO group, Dipartimento Energia, Politecnico di Torino , Italy
| | - S. Dulla
- NEMO group, Dipartimento Energia, Politecnico di Torino , Italy
| | - P. Ravetto
- NEMO group, Dipartimento Energia, Politecnico di Torino , Italy
| | - L. Savoldi
- NEMO group, Dipartimento Energia, Politecnico di Torino , Italy
| | - M. Utili
- ENEA, Centro Ricerche Brasimone , Italy
| | - R. Zanino
- NEMO group, Dipartimento Energia, Politecnico di Torino , Italy
| |
Collapse
|
18
|
Bonelli F, Boccaccini LV, Ghidersa BE, Kang Q, Savoldi L, Zanino R. Thermal-Hydraulic and Structural Analysis of a Helium-Cooled First Wall Mock-Up. Fusion Science and Technology 2017. [DOI: 10.13182/fst14-985] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
| | | | | | | | - L. Savoldi
- Dipartimento Energia, Politecnico di Torino, Torino, Italy
| | - R. Zanino
- Dipartimento Energia, Politecnico di Torino, Torino, Italy
| |
Collapse
|
19
|
Froio A, Bachmann C, Cismondi F, Savoldi L, Zanino R. Dynamic thermal-hydraulic modelling of the EU DEMO HCPB breeding blanket cooling loops. Progress in Nuclear Energy 2016. [DOI: 10.1016/j.pnucene.2016.08.007] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
20
|
Pagano M, Zanelli F, Bisagni A, Croci S, Braglia L, Savoldi L, Maramotti S, Pinto C. A possible correlation with the response in patients with metastatic lung caner: MicroRNA and Erlotinb. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw332.35] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
21
|
Cocconi G, Di Blasio B, Boni C, Bisagni G, Rondini E, Bella MA, Leonardi F, Savoldi L, Vallisneri C, Camisa R, Bruzzi P. Primary chemotherapy in operable breast carcinoma comparing CMF (cyclophosphamide, methotrexate, 5-fluorouracil) with an anthracycline-containing regimen: short-term responses translated into long-term outcomes. Ann Oncol 2005; 16:1469-76. [PMID: 15956038 DOI: 10.1093/annonc/mdi278] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND The role of anthracyclines has been extensively studied in adjuvant chemotherapy, but much less in the primary chemotherapy of early breast carcinoma. This study, comparing CMF (cyclophosphamide, methotrexate, 5-fluorouracil) with the rotational anthracycline-containing regimen CMFEV (CMF plus epirubicin and vincristine) administered as primary chemotherapy, demonstrated a significant increase in clinical complete response in premenopausal women. We report the long-term results. PATIENTS AND METHODS Two hundred and eleven patients with stage I or II palpable breast carcinoma and a tumour diameter of >2.5 cm were randomised to receive CMF or CMFEV for four cycles before surgery. After surgery, the patients in both arms received adjuvant CMF for three cycles. RESULTS In the study population as a whole, there was a non-significant 20% reduction in mortality and relapse rates in the CMFEV arm. However, the effect of the experimental regimen was only found in premenopausal patients, especially in terms of relapse-free survival (P=0.07) and locoregional relapse-free survival (P=0.0009), thus mirroring the effect on response rates. After 10 years, the proportions of premenopausal patients free from locoregional relapse as a first event in the CMF and CMFEV groups were 68% and 97%, respectively. No relevant differences were found in postmenopausal patients. CONCLUSION The overall results of this study showed that the greater activity of the experimental anthracycline-containing combination over CMF as primary chemotherapy in premenopausal patients translated into long-term effects in the same subgroup.
Collapse
Affiliation(s)
- G Cocconi
- Medical Oncology Division, Azienda Ospedaliera Universitaria of Parma, Italy.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Duchateau J, Fillunger H, Fink S, Heller R, Hertout P, Libeyre P, Maix R, Marinucci C, Martinez A, Meyder R, Nicollet S, Raff S, Ricci M, Savoldi L, Ulbricht A, Wuechner F, Zahn G, Zanino R. Test program preparations of the ITER toroidal field model coil (TFMC). Fusion Engineering and Design 2001. [DOI: 10.1016/s0920-3796(01)00570-1] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
23
|
Kato T, Tsuji H, Ando T, Takahashi Y, Nakajima H, Sugimoto M, Isono T, Koizumi N, Kawano K, Oshikiri M, Hamada K, Nunoya Y, Matsui K, Shinba T, Tsuchiya Y, Nishijima G, Kubo H, Hara E, Hanawa H, Imahashi K, Ootsu K, Uno Y, Oouchi T, Okayama J, Kawasaki T, Kawabe M, Seki S, Takano K, Takaya Y, Tajiri F, Tsutsumi A, Nakanura T, Hanawa H, Wakabayashi H, Nishii K, Hosogane N, Matsukawa M, Miura Y, Terakado T, Okano J, Shimada K, Yamashita M, Arai K, Ishigouoka T, Ninomiya A, Okuno K, Bessete D, Takigami H, Martovetsky N, Michael P, Takayasu M, Ricci M, Zanino R, Savoldi L, Zahn G, Martinez A, Maix R. First test results for the ITER central solenoid model coil. Fusion Engineering and Design 2001. [DOI: 10.1016/s0920-3796(01)00235-6] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
24
|
Boni C, Bisagni G, Savoldi L, Moretti G, Rondini E, Sassi M, Zadro A, De Pas T, Franciosi V, Pazzola A, Vignoli R, Banzi MC, Pajetta V. Gemcitabine, ifosfamide, cisplatin (GIP) for the treatment of advanced non-small cell lung cancer: a phase II study of the italian oncology group for clinical research (GOIRC). Int J Cancer 2000; 87:724-7. [PMID: 10925367] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/17/2023]
Abstract
The purpose of this study was to evaluate the activity and the toxicity of the combination of gemcitabine with ifosfamide and cisplatin (GIP) in chemonaive patients with advanced non small cell lung cancer (NSCLC). Eighty chemonaive patients with Stage IIIB-IV NSCLC were treated with the combination of gemcitabine 1 g/m(2) on Days 1 and 8, ifosfamide 2 g/m(2) on Day 1 and cisplatin 80 mg/m(2) on Day 2. Cycles were administered on an outpatient basis every 3 weeks. Hematologic toxicity was the main side effect; Grade III-IV thrombocytopenia was observed in 54 (67%) patients and Grade III-IV leucopenia in 44 (55%) patients, with 4 episodes of febrile neutropenia and 1 toxic death. Thirteen patients received platelet transfusions and 38 were transfused with packed red cells. All patients were evaluable for response. The overall response rate was 54% (95% confidence interval 43 to 65%) with 1 complete response. In patients with Stage IIIB and IV disease, response rates were 58% and 52%, respectively. Median time to progression was 40 weeks (range 0-114) and median overall survival was 12 months (16.6 months for stage IIIB and 10.4 months for stage IV). Median and minimum follow-up were 19 and 12 months, respectively. The GIP combination shows a response rate and overall survival of clinical interest. Hematologic toxicity was the main toxic effect, especially in patients with low performance status. This regimen will be tested in a Phase III randomized trial.
Collapse
Affiliation(s)
- C Boni
- Medical Oncology Service, Arcispedale S. Maria Nuova, Reggio Emilia, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Boni C, Bisagni G, Savoldi L, Moretti G, Rondini E, Sassi M, Zadro A, De Pas T, Franciosi V, Pazzola A, Vignoli R, Banzi M, Pajetta V. Gemcitabine, ifosfamide, cisplatin (GIP) for the treatment of advanced non-small cell lung cancer: A phase II study of the Italian oncology group for clinical research (goirc). Int J Cancer 2000. [DOI: 10.1002/1097-0215(20000901)87:5<724::aid-ijc15>3.0.co;2-n] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
26
|
Boni C, Bisagni G, Savoldi L, Moretti G, Vignoli R, Franciosi V, Pezzola A, De Pas M, Zadro A. Treatment of stage IIIB-IV non small cell lung cancer (NSCLC) with Gemcitabine, Ifosfamide, Cisplatin (GIP). A phase II study. Lung Cancer 1999. [DOI: 10.1016/s0169-5002(99)90826-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
27
|
Cocconi G, Bisagni G, Ceci G, Di Blasio B, De Lisi V, Passalacqua R, Zadro A, Boni C, Morandi P, Savoldi L. Three new active cisplatin-containing combinations in the neoadjuvant treatment of locally advanced and locally recurrent breast carcinoma: a randomized phase II trial. Breast Cancer Res Treat 1999; 56:125-32. [PMID: 10573105 DOI: 10.1023/a:1006246012448] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
We designed three new four-drug cisplatin-containing combinations and evaluated their activity in a randomized phase II study including patients with locally advanced (stage III) and locally recurrent breast carcinoma. All combinations included methotrexate (M) on day 1 and cisplatin (P) on day 2 (MVAC-like combinations) and differed from one another by the addition of Epirubicin (Epi), Vincristine (V), Etoposide (E), Mitomycin (Mi). Based on the administered agents, they were named MPEMi, MPEpiE, MPEpiV. The combinations were randomly assigned to 101 patients, 57 with locally advanced and 44 with locally recurrent breast carcinoma. Response was evaluated after 4 cycles. The complete response (CR) rates were 7% and 43% and the CR plus partial response (PR) rates were 84% and 89% in locally advanced and in locally recurrent disease, respectively. In locally advanced disease, a pathologic CR (pCR) was assessed in seven of 57 patients (12%). There were no significant differences among the three combinations. The toxicities were at times severe, but generally tolerable, as demonstrated by the high cumulative doses of the drugs received by the patients. In conclusion, these three innovative chemotherapy regimens induced high CR plus PR rates in the neoadjuvant treatment of stage III and of locally recurrent breast carcinoma, and a high rate of pCR in stage III disease. These regimens warrant testing in phase III trials.
Collapse
Affiliation(s)
- G Cocconi
- Medical Oncology Institution of Parma, Italian Oncology Group for Clinical Research (GOIRC), Italy.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Boni C, Savoldi L, Bisagni G, Ceci G, Crinò L, De Lisi V, Di Costanzo F, Lasagni L, Manenti AL, Moretti G, Rondini E, Sassi M, Zadro A. Bolus versus 5-day continuous infusion of cisplatin with mitomycin and vindesine in the treatment of advanced non-small cell lung cancer (NSCLC): a phase III prospective randomised trial of the Italian Oncology Group for Clinical Research (GOIRC). Eur J Cancer 1998; 34:1974-6. [PMID: 10023325 DOI: 10.1016/s0959-8049(98)00231-7] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
The aim of this randomised trial was to compare the efficacy of bolus versus continuous infusion cisplatin combined with mitomycin C and vindesine (MVP) for chemotherapy-naive patients with stage IIIB-IV non-small cell lung cancer (NSCLC). 97 patients (49 given bolus cisplatin-arm A and 48 given continuous infusion cisplatin--arm B) were evaluable for response. In arm A, 2 patients achieved a complete response (CR), 21 achieved a partial response (PR), whilst in arm B, 14 patients achieved a PR (29%) (P = 0.07). Median survival was 8 months in both arms. Myelosuppression was the most frequent and severe toxicity, with a higher incidence of grade 3-4 leucopenia in arm A when compared with arm B (44% versus 25%). In conclusion, there is no advantage for a cisplatin 5 day infusion in the MVP regimen.
Collapse
Affiliation(s)
- C Boni
- Medical Oncology Service, Arcispedale S. Maria Nuova, Reggio Emilia, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Bisagni G, Cocconi G, Ceci G, Di Blasio B, De Lisi V, Passalacqua F, Zadro A, Boni C, Morandi P, Savoldi L. P79 Three new highly active cisplatin-containing combinations in locally-advanced (stage III) and locally-recurrent breast carcinoma. A phase II randomized study. Eur J Cancer 1998. [DOI: 10.1016/s0959-8049(97)89296-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
30
|
Nizzoli R, Bozzetti C, Savoldi L, Manotti L, Naldi N, Camisa R, Soresi AP, Guazzi A, Cocconi G. Immunocytochemical assay of estrogen and progesterone receptors in fine needle aspirates from breast cancer patients. Acta Cytol 1994; 38:933-8. [PMID: 7992582] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
Estrogen receptors (ERs) and progesterone receptors (PRs) were determined by an immunocytochemical assay (ICA) on fine needle aspirates (FNAs) from patients with primary, recurrent and metastatic mammary carcinoma, and the results were compared to those with the biochemical dextran-coated charcoal (DCC) method performed on the surgical sample in order to compare the two methods. The aspirates were suspended in a buffered saline solution, cytocentrifuged onto glass slides and immunocytochemically stained according to the protocol of commercial kits employing monoclonal antibodies specific for ER and PR. Immunocytochemical staining of malignant cells was evaluated on the basis of the percentage of stained cells; 10% staining was taken as the cutoff value. Fine needle aspiration biopsies (FNABs) from 107 breast carcinomas were analyzed immunocytochemically for ER and 31 of them for PR, also. The overall concordance between ICA and DCC was 88% for ER and 87% for PR. The sensitivity, specificity, and positive and negative predictive value of ICA on FNAs as compared to conventional DCC were 87%, 90, 97% and 63%, respectively, for ER and 85%, 100%, 100% and 56% for PR. These findings suggest that estrogen immunocytochemical assays and progesterone immunocytochemical assays on FNAs in breast cancer patients are reliable techniques for evaluating receptor status and can be useful in assessing ER and PR whenever surgical biopsy is not indicated and when information about ER and PR status is required at the time of the clinical diagnosis.
Collapse
Affiliation(s)
- R Nizzoli
- Department of Oncology, City Hospital of Parma, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Bozzetti C, Nizzoli R, Naldi N, Manotti L, Savoldi L, Camisa R, Guazzi A, Cocconi G. Fine-needle aspiration technique for the concurrent immunocytochemical evaluation of multiple biologic parameters in primary breast carcinoma. Breast Cancer Res Treat 1994; 32:221-8. [PMID: 7865851 DOI: 10.1007/bf00665773] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Fine-needle aspiration cytology has been already established as a reliable method for the diagnosis of breast cancer. Its application has been recently extended to immunocytochemical analysis of biological parameters. In the current study estrogen and progesterone receptors, Ki67 growth fraction, and p53 protein expression were immunocytochemically evaluated on the cellular material sampled by the same fine-needle aspirate used for the conventional cytologic diagnosis of malignancy. Fine-needle aspiration specimens from 100 patients with primary breast carcinoma were submitted to the immunocytochemical analysis. Twenty-eight percent were in premenopause; 23% had tumors with a diameter less than 2 cm, 59% from 2 to 5 cm, and 18% more than 5 cm; 60% had axillary nodal status negative, 34% positive, and 6% unknown. The concomitant immunocytochemical evaluation of all parameters was possible in 70% of the patients. A significant association was found between p53 overexpression and Ki67 values (p = 0.004), and between Ki67 values and progesterone receptor status (p = 0.003). No correlation was found between any parameter and clinical tumor size. Estrogen (p = 0.02) and progesterone (p = 0.04) receptor negativity and high Ki67 growth fraction (p = 0.005) were significantly associated with the clinical evidence of axillary node involvement. This study suggests that fine-needle aspiration cytology represents an effective practice for a simultaneous evaluation of multiple biologic indicators and could be useful as a preoperative procedure in patients who are candidates for neoadjuvant chemotherapy and/or endocrine therapy.
Collapse
Affiliation(s)
- C Bozzetti
- Division of Medical Oncology, University Hospital, Parma, Italy
| | | | | | | | | | | | | | | |
Collapse
|